News German pricing rules hit Eisai's Halaven Drug has "no additional benefit" in metastatic liposarcoma, says IQWiG.
News Eisai angry over thyroid cancer drug impasse in England Thyroid cancer drug falls through gap in NHS funding
News Patients denied thyroid cancer drug in England Eisai considers legal action over funding "black hole".
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
